This content is machine translated Tofacitinib for ulcerative colitis Study shows real-world evidence for efficacy and safety The prevalence of ulcerative colitis (CU) in Switzerland is 1/500. The JAK inhibitor tofacitinib has been an arrow in the treatment quiver since 2019. In the phase 3 OCTAVE study,…
